Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.
Actively Recruiting
Researchers are evaluating the use of pioglitazone to improve kidney outcomes in people with ANCA-associated vasculitis, a condition that affects blood vessels and involves kidney inflammation. This multicenter, randomized controlled trial includes patients with biopsy-confirmed kidney involvement of ANCA vasculitis at diagnosis. The study aims mainly to see if pioglitazone can reduce kidney damage by improving protein levels in urine and serum creatinine. It also examines effects on blood pressure, metabolic changes from steroids, vasculitis activity, and safety in this group of patients. All participants receive standard immunosuppressive treatment combining corticosteroids and rituximab. They are randomly assigned to take either pioglitazone 30 mg daily or a placebo for 26 weeks alongside the standard care. Rituximab is given weekly for four weeks as induction, then re-administered every six months. Participants follow a predefined steroid tapering schedule. Biological samples are collected at multiple points throughout the study for analysis. Participants are followed for a total of 52 weeks with visits scheduled at weeks 1, 2, 3, 4, 8, 12, 26, 38, and 52. During these visits, kidney function, proteinuria, vasculitis activity, quality of life, and safety are assessed through clinical exams, blood and urine tests, and questionnaires. The primary outcome is measured at week 26, and secondary outcomes continue through week 52 to monitor effects and safety of pioglitazone over time.
Actively Recruiting
Researchers are evaluating ivonescimab as a potential treatment for patients with pleural mesothelioma whose cancer has returned after previous immunotherapy and standard chemotherapy. This is an open-label, single-arm phase II study involving about 38 patients who have relapsed after up to two prior lines of treatment, including immunotherapy with nivolumab 1 ipilimumab and standard chemotherapy. The trial aims to assess the disease control rate at 12 weeks after starting treatment with ivonescimab. Participants receive ivonescimab intravenously at a dose of 20 mgkg every three weeks, with a fixed dose of 3200 mg for patients weighing 160 kg or more. Treatment may continue for up to 24 months, or until disease progression, unacceptable side effects, withdrawal of consent, or other reasons for stopping. This study is conducted at approximately 20 centers and is designed as a single-group trial without a placebo or comparator group. During the study, participants will undergo regular assessments including CT scans to measure disease progression and response. Researchers will monitor safety and side effects from the start of treatment through up to 90 days after the last dose. They will also evaluate progression-free survival, overall survival, best response rate, and duration of response over a period of up to about 45 months. Participants are expected to comply with scheduled visits, treatment schedules, and laboratory tests throughout the study.
Actively Recruiting
Researchers are studying the use of the mylife CamAPS FX hybrid closed-loop insulin delivery system combined with the Dexcom G6 Continuous Glucose Monitoring sensor in people with type 1 diabetes T1D in France. This observational study aims to evaluate the systems impact on blood sugar control under real-life conditions over one year. It also explores participant experiences related to quality of life, treatment satisfaction, fear of low blood sugar, and sleep quality while tracking any complications related to the system. Participants include both adults and minors starting use of the system as part of their usual diabetes care. The study follows them for 12 months, collecting data on blood sugar control and system usage. There is no experimental treatment given instead, the study observes how the system performs when used in daily life by about 125 participants across multiple centers in France. Throughout the study, participants will complete self-reported questionnaires on quality of life and treatment experience at baseline, 3 months, and 12 months. Blood sugar data is gathered continuously from the glucose monitoring sensor to assess changes in time spent in target ranges and other glucose metrics. Safety is monitored by recording any adverse events related to the system. The study aims to understand how the system affects diabetes management and patient well-being over one year of use.
Actively Recruiting
Researchers are conducting a non-interventional observational study to follow patients with Chronic Obstructive Pulmonary Disease COPD who are treated with dupilumab as part of their usual medical care. The study aims to describe patient characteristics, assess safety, and evaluate patient-reported outcomes over a long-term period. This study will include about 350 to 500 participants across up to 50 sites in France. Participants will be observed for approximately 36 months without altering their routine treatment. The study collects data retrospectively and prospectively on patients newly started on dupilumab for COPD, as determined by their treating physician according to approved guidelines. There is no randomization or placebo group since this is an observational study. During the study, participants medical records and clinical data will be reviewed regularly to analyze demographics, disease history, treatment history, lung function, symptom assessments, and exacerbation rates. Researchers will track changes in lung function tests, COPD assessment scores, hospitalizations, adverse events, and reasons for treatment discontinuation over three years. Participants will not have to undergo additional treatments, but their health will be monitored as part of this long-term observational study.
Actively Recruiting
Researchers are evaluating pembrolizumab combined with carboplatin and taxane chemotherapy followed by pembrolizumab with or without maintenance sacituzumab tirumotecan sac-TMT as a first-line treatment for metastatic squamous non-small cell lung cancer NSCLC. This phase 3 study aims to determine if adding maintenance sac-TMT improves overall survival compared to pembrolizumab alone. Participants first undergo an induction phase consisting of four cycles of pembrolizumab every three weeks, carboplatin every three weeks, and either paclitaxel every three weeks or nab-paclitaxel weekly. After induction, participants are randomly assigned to receive either pembrolizumab maintenance alone or pembrolizumab combined with sac-TMT maintenance. The maintenance phase involves pembrolizumab every six weeks for up to 96 weeks and sac-TMT infusions every two weeks until discontinuation criteria are met. Throughout the study, participants will have tumor assessments, scans, and evaluations to monitor disease status, side effects, and quality of life. Researchers will measure overall survival up to approximately 50 months and progression-free survival up to 79 months, along with patient-reported symptoms such as dyspnea, cough, and chest pain. Safety monitoring includes tracking adverse events and treatment discontinuations. The total participation may last several years as long-term outcomes are assessed.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of two drug combinations for treating patients with hormone receptor-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. This phase 3, open-label, global study compares RLY-2608 zovegalisib plus fulvestrant against capivasertib plus fulvestrant following disease recurrence or progression after prior treatment with a CDK46 inhibitor. The study focuses on patients whose cancer has advanced locally or metastasized and have specific genetic mutations influencing treatment response. Participants will receive one of two treatment combinations zovegalisib taken orally twice daily together with fulvestrant given by intramuscular injection on specified days in a 28-day cycle, or capivasertib taken orally twice daily on an intermittent weekly schedule combined with the same fulvestrant regimen. Treatment cycles repeat every 28 days. The study will monitor and compare these combinations over several months to assess outcomes. Throughout the study, participants will undergo regular assessments including imaging scans to measure cancer progression, blood tests to monitor drug levels, and questionnaires to evaluate quality of life. Researchers will track progression-free survival, overall survival, response rates, duration of response, clinical benefit, and safety profiles. The study duration may extend up to approximately 77 months, with ongoing monitoring of health status and adverse events to gather comprehensive data on treatment impact.
Actively Recruiting
This research investigates GLSI-100 immunotherapy in people with HER2neu positive breast cancer who are at high risk for their cancer returning. It focuses on participants who have completed both neoadjuvant and postoperative adjuvant standard treatments. The study is Phase 3, randomized, double-blinded, and placebo-controlled, involving subjects who are HLA-A*02 positive as well as an open-label group of non-HLA-A*02 positive subjects. The goal is to evaluate the treatments impact on invasive breast cancer-free survival over a median follow-up of 4 years. Participants receive 6 primary immunization injections of GLSI-100 or placebo intradermally once a month for the first 6 months, followed by 5 booster injections spaced 6 months apart, totaling 11 injections over 3 years. There are three groups one receiving placebo 0.9% normal saline, one receiving GLSI-100 immunotherapy in HLA-A*02 positive subjects, and an open-label arm for non-HLA-A*02 positive subjects receiving GLSI-100 under the same schedule. During the study, participants undergo regular monitoring and assessments including invasive disease-free survival, distant disease-free survival, overall survival, and quality of life questionnaires at baseline and up to 36 months. Researchers track safety and treatment effects over a median 4-year follow-up. The study continues until December 2031, aiming to provide comprehensive data on long-term outcomes and quality of life for participants receiving these treatments.
Actively Recruiting
Researchers are evaluating the safety and performance of the SYMBOL range of medical devices used in total hip arthroplasty hip replacement surgery. This observational study aims to monitor outcomes over a period of 10 years in patients who receive these devices, assessing their durability and overall impact on hip joint health. The study is sponsored by Dedienne Sante S.A.S. and focuses on conditions such as degenerative hip joint disease, post-traumatic osteoarthritis, hip arthritis, femoral neck fractures, avascular necrosis of the femoral head, and failure of prosthetic joint implants. Participants undergo total hip arthroplasty involving at least one medical device from the SYMBOL range. The study includes patients receiving either primary or revision hip replacement surgery with these devices. There is no randomized assignment or placebo group, as this is an observational follow-up of patients treated with SYMBOL devices. The study spans up to 10 years post-operation, with specific evaluation timepoints at 6 months, 18 months, 5 years, and 10 years after surgery. During the study, participants will have regular assessments including radiographic evaluations to check for implant stability and bone changes, as well as clinical evaluations using the Harris Hip Score and pain intensity scales. Patient-reported measures such as quality of life EQ-5D-5L and satisfaction with the hip joint will also be collected. The main outcome measure is the survivorship of individual SYMBOL orthopaedic components 10 years after surgery. Safety will be monitored by recording any adverse device effects throughout the study period, with follow-up lasting an average of 10 years.
Actively Recruiting
Researchers are evaluating whether certain women with early-stage, low-risk hormone receptor-positive and HER2-negative breast cancer can safely skip hormone therapy after surgery and possibly radiation therapy. This study focuses on postmenopausal women aged 60 and older with small tumors that have a very low risk of recurrence. It aims to compare outcomes for those who avoid hormone treatment with others who received standard hormone therapy in a different study, while also assessing their risk of cancer return, cardiovascular and bone health, and quality of life. Participants will not receive any hormone therapy such as tamoxifen or aromatase inhibitors during the study. All participants must have had surgery to remove the tumor, and if breast-conserving surgery was performed, they should have received or be scheduled for radiotherapy within three months after surgery. No chemotherapy will be given or planned. The study will enroll participants for two years, followed by up to five years of monitoring after the last person joins to observe long-term cancer recurrence and other health outcomes. During the study, participants will attend scheduled visits for medical evaluations, laboratory tests, and complete quality of life and mood questionnaires at baseline, 6 months, 1 year, and annually thereafter until five years after the last participant is enrolled. Researchers will monitor cancer recurrence rates, bone and cardiovascular events, and overall survival. This comprehensive follow-up aims to understand the effects of avoiding hormone therapy on both cancer outcomes and participants wellbeing over time.
1-10 of 11
1